Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms.

ABSTRACT:

Background

Transthyretin amyloid cardiomyopathy (ATTR-CM) is increasingly recognized as a treatable cause of heart failure (HF). Advances in diagnosis and therapy have increased the number of patients diagnosed at early stages, but prognostic data on patients without HF symptoms are lacking. Moreover, it is unknown whether asymptomatic patients benefit from early initiation of transthyretin (TTR) stabilizers.

Objectives

The aim of this study was to describe the natural history and prognosis of ATTR-CM in patients without HF symptoms.

Methods

Clinical characteristics and outcomes of patients with ATTR-CM without HF symptoms were retrospectively collected at 6 international amyloidosis centers.

Results

A total of 118 patients (78.8% men, median age 66 years [IQR:

SUBMITTER: Gonzalez-Lopez E 

PROVIDER: S-EPMC9700255 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature